{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:21:20Z","timestamp":1777544480095,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81822016"],"award-info":[{"award-number":["81822016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771382"],"award-info":[{"award-number":["81771382"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12272-020-01258-7","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T09:24:55Z","timestamp":1596273895000},"page":"765-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19"],"prefix":"10.1007","volume":"43","author":[{"given":"Li","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhentao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,1]]},"reference":[{"key":"1258_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40249-020-00646-x","volume":"9","author":"SP Adhikari","year":"2020","unstructured":"Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, Sun C, Sylvia S, Rozelle S, Raat H, Zhou H (2020) Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 9:29. https:\/\/doi.org\/10.1186\/s40249-020-00646-x","journal-title":"Infect Dis Poverty"},{"key":"1258_CR2","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/jac\/dkv018","volume":"70","author":"MA Al-Bari","year":"2015","unstructured":"Al-Bari MA (2015) Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70:1608\u20131621. https:\/\/doi.org\/10.1093\/jac\/dkv018","journal-title":"J Antimicrob Chemother"},{"key":"1258_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000024948","volume":"41","author":"NE Bishop","year":"1998","unstructured":"Bishop NE (1998) Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology 41:261\u2013271. https:\/\/doi.org\/10.1159\/000024948","journal-title":"Intervirology"},{"key":"1258_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"C Chatre","year":"2018","unstructured":"Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM (2018) Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 41:919\u2013931. https:\/\/doi.org\/10.1007\/s40264-018-0689-4","journal-title":"Drug Saf"},{"key":"1258_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/15563650500514558","volume":"44","author":"CY Chen","year":"2006","unstructured":"Chen CY, Wang FL, Lin CC (2006) Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 44:173\u2013175. https:\/\/doi.org\/10.1080\/15563650500514558","journal-title":"Clin Toxicol (Phila)"},{"key":"1258_CR6","first-page":"215","volume":"49","author":"J Chen","year":"2020","unstructured":"Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D (2020a) A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban 49:215\u2013219","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"1258_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.2004075","author":"Z Chen","year":"2020","unstructured":"Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z (2020b) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. https:\/\/doi.org\/10.1101\/2020.03.22.2004075","journal-title":"MedRxiv"},{"key":"1258_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","volume":"57","author":"A Cortegiani","year":"2020","unstructured":"Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 57:279\u2013283. https:\/\/doi.org\/10.1016\/j.jcrc.2020.03.005","journal-title":"J Crit Care"},{"key":"1258_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","volume":"31","author":"J Ducharme","year":"1996","unstructured":"Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 31:257\u2013274. https:\/\/doi.org\/10.2165\/00003088-199631040-00003","journal-title":"Clin Pharmacokinet"},{"key":"1258_CR10","unstructured":"EMA(European Medicines Agency) (2020) COVID-19: chloroquine and hydroxychloroquine only be used in clinical trials or emergency use programmes. Available at European Medicines Agency document Website https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes_en.pdf. Accessed 1 Apr 2020"},{"key":"1258_CR11","unstructured":"FDA(US Food & Drug Administration) (2020) Re: Request for Emergency Use Authorization For Use of Chloroquine Phoslhate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Covrnavirus Disease. US Food & Drug Administration official Website. Available at https:\/\/www.fda.gov\/media\/136534\/download. Accessed 29 Mar 2020"},{"key":"1258_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1365-2125.1983.tb01540.x","volume":"15","author":"M Frisk-Holmberg","year":"1983","unstructured":"Frisk-Holmberg M, Bergqvist Y, Englund U (1983) Chloroquine intoxication. Br J Clin Pharmacol 15:502\u2013503. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb01540.x","journal-title":"Br J Clin Pharmacol"},{"key":"1258_CR13","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1177\/0961203396005001041","volume":"5","author":"DE Furst","year":"1996","unstructured":"Furst DE (1996) Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5:S11\u2013S15","journal-title":"Lupus"},{"key":"1258_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D (2020a) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","journal-title":"Int J Antimicrob Agents"},{"key":"1258_CR15","doi-asserted-by":"publisher","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","volume":"34","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira VE, Tissot-Dupont HT, Honor\u00e9 S, Stein A, Million M, Colson P, La Scola B, Veit V, Jacquier A, Deharo JC, Drancourt M, Fournier PE, Rolain JM, Brouqui P, Raoult D (2020b) Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Travel Med Infect Dis 34:101663. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101663","journal-title":"Travel Med Infect Dis"},{"key":"1258_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40779-020-00240-0","volume":"7","author":"YR Guo","year":"2020","unstructured":"Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u2013an update on the status. Mil Med Res 7:10\u201311. https:\/\/doi.org\/10.1186\/s40779-020-00240-0","journal-title":"Mil Med Res"},{"key":"1258_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395:497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5","journal-title":"The Lancet"},{"key":"1258_CR19","unstructured":"Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly CA, Riley S, Ferguson NM (2020) Report 3: transmissibility of 2019-nCoV. Feminine-Perspective Magazine Web. Available at https:\/\/fpmag.net\/wp-content\/uploads\/2020\/01\/Imperial-2019-nCoV-transmissibility.pdf. Accessed 29 Mar 2020"},{"key":"1258_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1099\/0022-1317-4-2-203","volume":"4","author":"AD Inglot","year":"1969","unstructured":"Inglot AD (1969) Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol 4:203\u2013214. https:\/\/doi.org\/10.1099\/0022-1317-4-2-203","journal-title":"J Gen Virol"},{"key":"1258_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","volume":"323","author":"E Keyaerts","year":"2004","unstructured":"Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323:264\u2013268. https:\/\/doi.org\/10.1016\/j.bbrc.2004.08.085","journal-title":"Biochem Biophys Res Commun"},{"key":"1258_CR22","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1128\/AAC.01509-08","volume":"53","author":"E Keyaerts","year":"2009","unstructured":"Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P (2009) Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53:3416\u20133421. https:\/\/doi.org\/10.1128\/AAC.01509-08","journal-title":"Antimicrob Agents Chemother"},{"key":"1258_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s0162-0134(02)00633-5","volume":"94","author":"R Legssyer","year":"2003","unstructured":"Legssyer R, Josse C, Piette J, Ward RJ, Crichton RR (2003) Changes in function of iron-loaded alveolar macrophages after in vivo administration of desferrioxamine and\/or chloroquine. J Inorg Biochem 94:36\u201342. https:\/\/doi.org\/10.1016\/s0162-0134(02)00633-5","journal-title":"J Inorg Biochem"},{"key":"1258_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ebiom.2017.09.034","volume":"24","author":"C Li","year":"2017","unstructured":"Li C, Zhu X, Ji X, Quanquin N, Deng YQ, Tian M, Aliyari R, Zuo X, Yuan L, Afridi SK, Li XF, Jung JU, Nielsen-Saines K, Qin FX, Qin CF, Xu Z, Cheng G (2017) Chloroquine, a FDA-approved drug, prevents Zika Virus infection and its associated congenital microcephaly in mice. EBioMedicine 24:189\u2013194. https:\/\/doi.org\/10.1016\/j.ebiom.2017.09.034","journal-title":"EBioMedicine"},{"key":"1258_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16. https:\/\/doi.org\/10.1038\/s41421-020-0156-0","journal-title":"Cell Discov"},{"key":"1258_CR27","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology (2016) Recommendations on screening for chloroquine and hydroxychloroquine etinopathy (2016 Revision). Ophthalmology 123:1386\u20131394. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.058","journal-title":"Ophthalmology"},{"key":"1258_CR17","unstructured":"Mediterranee-infection Hospital (2020) Countries and regions where hydroxychloroquine and chloroquine are recommended to fight coronavirus. Available at Mediterranee-infection Hospital Website https:\/\/www.mediterranee-infection.com\/coronavirus-pays-ou-lhydroxychloroquine-est-recommandee. Accessed 28 Mar 2020"},{"key":"1258_CR28","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1016\/S2214-109X(20)30114-5","volume":"8","author":"O Mitj\u00e0","year":"2020","unstructured":"Mitj\u00e0 O, Clotet B (2020) Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health 8:e639\u2013e640. https:\/\/doi.org\/10.1016\/S2214-109X(20)30114-5","journal-title":"Lancet Glob Health"},{"key":"1258_CR29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","volume":"50","author":"JM Molina","year":"2020","unstructured":"Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N (2020) No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 50:384. https:\/\/doi.org\/10.1016\/j.medmal.2020.03.006","journal-title":"Med Mal Infect"},{"key":"1258_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5539\/gjhs.v8n3p59","volume":"8","author":"Q Motarjemizadeh","year":"2015","unstructured":"Motarjemizadeh Q, Aidenloo NS, Abbaszadeh M (2015) Detection of hydroxychloroquine retinal toxicity by automated perimetry in 60 rheumatoid arthritis patients with normal fundoscopic findings. Glob J Health Sci 8:59\u201364. https:\/\/doi.org\/10.5539\/gjhs.v8n3p59","journal-title":"Glob J Health Sci"},{"key":"1258_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1742-4690-4-6","volume":"4","author":"MA Naarding","year":"2007","unstructured":"Naarding MA, Baan E, Pollakis G, Paxton WA (2007) Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology 4:6. https:\/\/doi.org\/10.1186\/1742-4690-4-6","journal-title":"Retrovirology"},{"key":"1258_CR32","doi-asserted-by":"crossref","unstructured":"Piller C (2020) Former FDA leaders decry emergency authorization of malaria drugs for coronavirus. Science Magazine NewWeb. Available at https:\/\/www.sciencemag.org\/news\/2020\/04\/former-fda-leaders-decry-emergency-authorization-malaria-drugs-coronavirus. Accessed 7 Apr 2020","DOI":"10.1126\/science.abc1337"},{"key":"1258_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","volume":"38","author":"D Plantone","year":"2018","unstructured":"Plantone D, Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig 38:653\u2013671. https:\/\/doi.org\/10.1007\/s40261-018-0656-y","journal-title":"Clin Drug Investig"},{"key":"1258_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0042-6822(90)90099-d","volume":"174","author":"VB Randolph","year":"1990","unstructured":"Randolph VB, Winkler G, Stollar V (1990) Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174:450\u2013458. https:\/\/doi.org\/10.1016\/0042-6822(90)90099-d","journal-title":"Virology"},{"key":"1258_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155\u2013166. https:\/\/doi.org\/10.1038\/s41584-020-0372-x","journal-title":"Nat Rev Rheumatol"},{"key":"1258_CR36","unstructured":"Sermo.Com (2020) Breaking Results: Sermo\u2019s COVID-19 Real Time Barometer Study. Available at Sermo\u2019s COVID-19-Barometer Web https:\/\/public-cdn.sermo.com\/covid19\/c8\/be4e\/4edbd4\/dbd4ba4ac5a3b3d9a479f99cc5\/wave-i-sermo-covid-19-global-analysis-final.pdf. Accessed 27 Mar 2020."},{"key":"1258_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/2020.01.23.916726","author":"M Shen","year":"2020","unstructured":"Shen M, Peng Z, Xiao Y, Zhang L (2020) Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. Biorxiv. https:\/\/doi.org\/10.1101\/2020.01.23.916726","journal-title":"Biorxiv"},{"key":"1258_CR38","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1099\/0022-1317-64-5-1149","volume":"64","author":"M Shibata","year":"1983","unstructured":"Shibata M, Aoki H, Tsurumi T, Sugiura Y, Nishiyama Y, Suzuki S, Maeno K (1983) Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. J Gen Virol 64:1149\u20131156. https:\/\/doi.org\/10.1099\/0022-1317-64-5-1149","journal-title":"J Gen Virol"},{"key":"1258_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.161063","volume":"44","author":"A Srinivasa","year":"2017","unstructured":"Srinivasa A, Tosounidou S, Gordon C (2017) Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue? J Rheumatol 44:398. https:\/\/doi.org\/10.3899\/jrheum.161063","journal-title":"J Rheumatol"},{"key":"1258_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.antiviral.2017.11.017","volume":"149","author":"YW Tan","year":"2018","unstructured":"Tan YW, Yam WK, Sun J, Chu JJH (2018) An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. Antiviral Res 149:143\u2013149. https:\/\/doi.org\/10.1016\/j.antiviral.2017.11.017","journal-title":"Antiviral Res"},{"key":"1258_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0001-706x(02)00056-6","volume":"83","author":"O Tasanor","year":"2002","unstructured":"Tasanor O, Noedl H, Na-Bangchang K, Congpuong K, Sirichaisinthop J, Wernsdorfer WH (2002) An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine. Acta Trop 83:49\u201361. https:\/\/doi.org\/10.1016\/s0001-706x(02)00056-6","journal-title":"Acta Trop"},{"key":"1258_CR42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3109\/08923973.2013.780078","volume":"35","author":"E T\u00f6nnesmann","year":"2013","unstructured":"T\u00f6nnesmann E, Kandolf R, Lewalter T (2013) Chloroquine cardiomyopathy\u2014a review of the literature. Immunopharmacol Immunotoxicol 35:434\u2013442. https:\/\/doi.org\/10.3109\/08923973.2013.780078","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1258_CR43","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","volume":"177","author":"F Touret","year":"2020","unstructured":"Touret F, de Lamballerie X (2020) Of chloroquine and COVID-19. Antiviral Res 177:104762. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104762","journal-title":"Antiviral Res"},{"key":"1258_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https:\/\/doi.org\/10.1186\/1743-422X-2-69","journal-title":"Virol J"},{"key":"1258_CR45","unstructured":"Voss A (2020) Official Statement from International Society of Antimicrobial Chemotherapy (ISAC). Available at International Society of Antimicrobial Chemotherapy PublicationWeb https:\/\/www.isac.world\/news-and-publications\/official-isac-statement. Accessed 3 Apr 2020."},{"key":"1258_CR46","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020a) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061\u20131069. https:\/\/doi.org\/10.1001\/jama.2020.1585","journal-title":"JAMA"},{"key":"1258_CR47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020b) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0","journal-title":"Cell Res"},{"key":"1258_CR48","unstructured":"WHO(World Helth Organization) (2020) Coronavirus disease (COVID-19) Situation Dashboard. Available at World Helth Organization Offical Web https:\/\/www.who.int\/redirect-pages\/page\/novel-coronavirus-(covid-19)-situation-dashboard. Accessed 30 Apr 2020"},{"key":"1258_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180:1\u201311. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994","journal-title":"JAMA Intern Med"},{"key":"1258_CR50","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/cr.2012.165","volume":"23","author":"Y Yan","year":"2013","unstructured":"Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, Jin N, Jiang C (2013) Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 23:300\u2013302. https:\/\/doi.org\/10.1038\/cr.2012.165","journal-title":"Cell Res"},{"key":"1258_CR51","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.cjca.2014.08.016","volume":"30","author":"H Yogasundaram","year":"2014","unstructured":"Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, Ringrose J, Oudit GY (2014) Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol 30:1706\u20131715. https:\/\/doi.org\/10.1016\/j.cjca.2014.08.016","journal-title":"Can J Cardiol"},{"key":"1258_CR52","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/all.14238","volume":"75","author":"JJ Zhang","year":"2020","unstructured":"Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD (2020) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75:1730\u20131741. https:\/\/doi.org\/10.1111\/all.14238","journal-title":"Allergy"},{"key":"1258_CR53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12640-017-9855-1","volume":"34","author":"L Zou","year":"2018","unstructured":"Zou L, Xue Y, Jones M, Heinbockel T, Ying M, Zhan X (2018) The effects of quinine on neurophysiological properties of dopaminergic neurons. Neurotox Res 34:62\u201373. https:\/\/doi.org\/10.1007\/s12640-017-9855-1","journal-title":"Neurotox Res"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-020-01258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-020-01258-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-020-01258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T23:44:05Z","timestamp":1627775045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-020-01258-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1007\/s12272-020-01258-7","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}